Arkolith/Insider Trading/SYRS/Form 4

Simonian Nancy A

DirectorSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Dec 5, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
0 non-derivative · 5 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 1, 2023Disposed to issuer(D)8K——0
Dec 1, 2023Disposed to issuer(D)17K——0
Dec 1, 2023Disposed to issuer(D)30K——0
Dec 1, 2023Disposed to issuer(D)29K——0
Dec 1, 2023Disposed to issuer(D)28K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-23-068283) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML